Evidence that natural immunity is long lasting and on par with the vaccine's initial levels of protection:
Oct 28, 2021
> Anti-SARS-CoV-2 antibodies were identified in 97% of COVID-19 convalescent donors at initial presentation. In follow-up analyses, of 116 donors presenting at repeat time points, 91.4% had detectable IgG levels up to 11 months after symptom recovery
https://pubmed.ncbi.nlm.nih.gov/34089610/
Aug 25, 2021
> Model 1 ... found that cases in the vaccinated group (n=238, 1.5%) were 13 fold more likely to experience a breakthrough infection than the natural immunity group
> Model 2 ... found that cases in the vaccinated group (n=640, 1.4%) were 6-fold more likely to experience a breakthrough infection than the natural immunity group
> Model 3 ... found that cases in the infection-vaccine group (n=20, 0.14%) had about half the risk of experiencing a breakthrough infection than the natural immunity group
https://ncrc.jhsph.edu/research/comparing-sars-cov-2-natural...
June, 2021
> The presence of IgG antibodies to nucleocapsid protein was associated with substantially reduced risk of reinfection in staff and residents for up to 10 months after primary infection.
https://www.thelancet.com/journals/lanhl/article/PIIS2666-75...
Jan 26, 2021
> As with antibodies, the numbers of different immune cell types varied substantially between individuals. Neither gender nor differences in disease severity could account for this variability. However, 95% of the people had at least 3 out of 5 immune-system components that could recognize SARS-CoV-2 up to 8 months after infection.
https://www.nih.gov/news-events/nih-research-matters/lasting...